Based on studies showing terpenoids as modulators of KRAS regulated downstream molecular pathways, we asked if this chemical family has an affinity of inhibiting KRAS protein activity. ...These data suggest that the selected members of the triterpene family such as lupeol could be exploited as clinical agents for preventing the disease progression in KRAS driven cancers which however warrants further investigation....